Monday, 25 Sep 2017

You are here

Pharma Pays $8.2 Billion to Physicians in 2016

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

While research expenditures ($4.36 billion) made up more than half of this amount, the remainder includes funds distributed to cover expenses like travel, gifts, speaking fees and meals ($2.8 billion in "general payments"). 

The top three payouts came from Roche ($586 million), Novartis and Pfizer ($475 million each). Novartis, Pfizer and AstraZeneca spent the most on research payments ($450 million, $430 million, $367 million, respectively).

The detailed data also highlights the complexity of multinational drug companies' corporate structures. Pfizer, for instance, reported payments made through 14 different corporate entities. J&J and Roche each had more than ten reporting bodies, if the wholly owned subsidiaries of Janssen and Genentech, respectively, are included. 

For more info on open payments or payments made to individual physicians go to: https://openpaymentsdata.cms.gov/summary.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

While these numbers are somewhat alarming and reflect speaker fees, consultant fees and meals, I wonder if they also include payment for services performed in clinical trials. Physicians work hard in clinical research and deserve fair reimbursement. I am aware that early on the Sunshine Act inappropriately posted these numbers. Of course payments often go to salary for study coordinators, IRB, etc and do not end up entirely in the physicians pocket book.

More Like This

22 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.